MAR 18, 2017 5:58 PM PDT

Lung Cancer Patients may Benefit From Advanced Proton Therapy

WRITTEN BY: Carmen Leitch

There could be some good news for patients dealing with recurrent lung cancer. One type of radiation treatment, called intensity modulated proton therapy (IMPT), has shown promise in preliminary testing. Researchers at The University of Texas MD Anderson Cancer Center treated patients by reirradiating with IMPT. The majority of those patients had no cancer recurrence within one year of treatment. In addition, few people were subjected to side effects. The data from the research was reported at the 2017 Multidisciplinary Thoracic Cancers Symposium.

Lung cancer is a devastating disease, and recurrence is the main reason that people die. The American Cancer Society estimates that 155,870 die from the disease annually, while 222,500 people are newly diagnosed. Currently, none of the typical treatment options are very good and it is often not a condition that surgery can alleviate.  Jennifer Ho, M.D., resident, Radiation Oncology explained that because the treatment options are poor, there is interest in using radiation as a therapeutic.

"Historically, repeat radiation at a higher, curative dose was not possible with older, less precise radiation techniques because the cumulative radiation dose necessary to treat the cancer would cause too much toxicity," explained lead author of the work, Ho. "In lung cancer, tumors are close to the esophagus, aorta and spinal cord, and all of these critical structures are vital for the body to function. The proton beam - and pencil beam in particular - provides much more conformal radiation, which means higher doses to tumors and lower dosages to critical structures nearby."

IMPT is one of the most advanced proton therapies, using scanning beam technology as a foundation to both optimize intensities and energies of all pencil beams to send a targeted dose of protons to tumors, explained Joe Y. Chang, M.D., Ph.D., a Professor of Radiation Oncology. "The technology has the ability to destroy cancer cells while sparing surrounding healthy tissue from damage. Therefore, important quality of life outcomes can be preserved and severe toxicities have shown to be reduced," said Chang, the corresponding author of the report.

While it was a relatively small study which employed a retrospective analysis, the investigators learned that of 27 patients given IMPT to treat lung cancer recurrence, after one year, 61 percent of the patients did not have a recurrence in the chest and lung. The researchers also found that those that received higher doses of radiation had fewer local recurrences and better progression-free survival. The radiation therapy was also tolerated well by the patients. 

"With the advancement of IMPT, we knew that we were able to generate more precise radiation treatment plans that spared normal tissue, but we weren't sure if this would translate into beneficial clinical outcomes until we analyzed this data," said Chang. "While the findings are early, we're hopeful that we can offer more positive outcomes and low toxicity with IMPT for recurrent thoracic cancer patients who previously had few treatment options."

 

You can learn more about IMPT in the video, from MD Anderson Proton Therapy Center.

Sources: AAAS/Eurekalert! via University of Texas MD Anderson Cancer Center, American Cancer Society

About the Author
  • Experienced research scientist and technical expert with authorships on 28 peer-reviewed publications, traveler to over 60 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
NOV 16, 2019
Cancer
NOV 16, 2019
Understanding H. pylori and gastric cancer
New research published in the journal Gastroenterology offers insight on gastric cancer and the presence of the common bacteria known as H. pylori (Helicob...
JAN 13, 2020
Cancer
JAN 13, 2020
The anti-cancer properties of bitter melon
New research published in the journal Cell Communication and Signaling suggests that bitter melon, also known as bitter gourd, may have anti-cancer propert...
JAN 14, 2020
Cancer
JAN 14, 2020
Could the flu vaccine shrink cancer tumors?
If you’ve been to the doctor recently, you’ve probably been asked if you want a flu shot this year. The flu vaccine is popular because it reduc...
JAN 21, 2020
Drug Discovery & Development
JAN 21, 2020
Drug Targets Gastrointestinal Cancer
The FDA has recently approved Ayvakit (avapritinib) for the treatment of unresectable and metastatic gastrointestinal stromal tumor (GIST) that occurs most...
FEB 01, 2020
Cancer
FEB 01, 2020
How does infrared light affect our skin?
New research published recently in The FASEB Journal reports, at last, the effects of visible and infrared light on our skin. According to the study, UV, v...
FEB 14, 2020
Cancer
FEB 14, 2020
Cataloging Cancer: DNA fingerprints at work
New research published as part of a global Pan-Cancer Project highlights the world’s most comprehensive catalog to date of DNA fingerprints of cancer...
Loading Comments...